Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K39/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2021/086159PROTEIN FUSED WITH MOLECULE CAPABLE OF BINDING TO IMMUNE CHECKPOINT MOLECULE AND USE OF SAME
WO 06.05.2021
Int.Class C07K 14/47
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
Appl.No PCT/KR2020/015165 Applicant CELLEMEDY CO.,LTD Inventor LEE, Jee Won
The present invention relates to a protein fused with a disease antigen and a use of same. The protein of the present invention is formed via self-assembly of ferritin monomers fused with a disease antigen epitope. The protein of the present invention exhibits excellent binding affinity to a human transferrin receptor, and thus can provide disease antigen epitopes of various kinds and lengths to antigen-presenting cells to induce an immune response to the corresponding antigen.
2.WO/2021/086909COMBINATION OF A PD-1 ANTAGONIST, A VEGFR/FGFR/RET TYROSINE KINASE INHIBITOR AND A CBP/BETA-CATENIN INHIBITOR FOR TREATING CANCER
WO 06.05.2021
Int.Class A61K 31/47
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
Appl.No PCT/US2020/057650 Applicant EISAI R&D MANAGMENT CO., LTD. Inventor OZAWA, Yoichi
The present disclosure describes a combination therapy comprising an antagonist of Programmed Death 1 receptor (PD-1), a lenvatinib or a pharmaceutically acceptable salt thereof, and (6S,9aS)-N- benzyl-8-({6-[3-(4-ethylpiperazin-l-yl)azetidin-l-yl]pyridin-2- yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-l- yl)hexahydro-2H-pyrazino[2,l-c][l,2,4]triazine-l(6H)-carboxamide (E7386) or a pharmaceutically acceptable salt thereof, and the use of the combination therapies for the treatment of a cancer.
3.20210128723COMBINATION OF ATR KINASE INHIBITORS AND PD-1/PD-L1 INHIBITORS
US 06.05.2021
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No 16635812 Applicant Bayer Pharma Aktiengesellschaft Inventor Antje Margret WENGNER

The present invention covers combinations of at least two components, component A and component B, comprising component A being an inhibitor of ATR kinase, particularly an inhibitor of ATR kinase selected from VX-803, VX-970, AZD-6738, a compound of general formula (I) described herein, a compound of general formula (lb) described herein and Compound A described infra, and component B being a PD-1/PD-L1 inhibitor described herein. Another aspect of the present invention covers the use of such combinations as described herein for the preparation of a medicament for the treatment or prophylaxis of a disease, particurlarly for the treatment of a hyper-proliferative disease.

4.WO/2021/083370PREPARATION AND USE OF NANOMATERIAL SPECIFICALLY ACTIVATING IMMUNE SYSTEM
WO 06.05.2021
Int.Class A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
Appl.No PCT/CN2020/125506 Applicant SHENZHEN INSTITUTES OF ADVANCED TECHNOLOGY Inventor CAI, Lintao
Disclosed are a nanoparticle that can be used for tumor photothermal therapy and medical imaging, and a method for preparing a polyethylene glycol-IR-797-DC cell membrane nanoparticle (DC-NP), the method comprising wrapping an antigen-loaded DC cell membrane on a particle skeleton formed by phospholipid polyethylene glycol amino (DSPE-PEG) and IR-797 triggered by near-infrared light, thereby forming a polyethylene glycol-IR-797-DC cell membrane nanoparticle (DC-NP) that promotes the enrichment, proliferation, activation and near-infrared light absorption of T cells at a tumor site. The method synergistically improves the effect of low-temperature photothermal anti-tumor therapy by means of enhancing the immune response of a body.
5.WO/2021/085650VACCINE
WO 06.05.2021
Int.Class A61K 39/145
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
145Orthomyxoviridae, e.g. influenza virus
Appl.No PCT/JP2020/041112 Applicant NEROME INSTITUTE OF BIOLOGICAL RESOURCES Inventor NEROME Kuniaki
The objective is to provide a novel, highly effective vaccine. The present invention relates to a vaccine comprising a virus-like particle containing an immunomodulator molecule, wherein: the immunomodulator molecule includes interleukin-12 protein, a neuraminidase (NA) domain region originating from NA protein, and an M2 protein domain region originating from an influenza virus; the NA domain region includes an extramembrane domain, a transmembrane domain, and an intracellular domain; the M2 protein domain region includes an extramembrane domain, a transmembrane domain, and an intracellular domain; the interleukin-12 protein is bound to the extramembrane domain in the NA domain region; and the intracellular domain in the M2 protein domain region is bound to the intracellular domain in the NA domain region via a linker.
6.WO/2021/087015ENGINEERED ANTIBODIES TO HIV ENV
WO 06.05.2021
Int.Class A61K 39/42
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
42viral
Appl.No PCT/US2020/057816 Applicant INTERNATIONAL AIDS VACCINE INITIATIVE Inventor SOK, Devin
The present disclosure relates to anti-HIV Env antibodies and their use in the treatment or prevention of HIV/AIDS. In one aspect, provided herein are enhanced engineered anti-HIV Env antibodies that were derived from the PGDM1400 parent antibody using directed-evolution and yeast display. In one aspect, provided herein are pharmaceutical compositions comprising the enhanced engineered anti-HIV Env antibodies disclosed herein.
7.WO/2021/083409ANTI-CD97 MONOCLONAL ANTIBODY, VARIABLE REGION AND CONSTANT REGION SEQUENCES THEREOF, AND ANTI-BRAIN TUMOR APPLICATION
WO 06.05.2021
Int.Class C07K 16/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
Appl.No PCT/CN2020/137694 Applicant HENAN UNIVERSITY Inventor YIN, Jinlong
An anti-CD97 monoclonal antibody, variable region and constant region sequences thereof, and application thereof. The variable region sequences of the anti-CD97 monoclonal antibody comprise nucleotide sequences such as a heavy chain sequence as represented by SEQ ID NO: 1 and a light chain sequence as represented by SEQ ID NO: 2. The anti-CD97 monoclonal antibody prepared with the variable region sequences is able to bind specifically to CD97, and may be used in the preparation of medication for treating diseases (such as brain tumor) related to excessive or uncontrolled expression of CD97.
8.WO/2021/086889METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND INFECTIOUS DISEASES
WO 06.05.2021
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/US2020/057619 Applicant CHINOOK THERAPEUTICS, INC. Inventor DESBIEN, Anthony Lloyd
The present invention relates to methods and compositions for the treatment of diseases with STING agonists. As described hereinafter, STING activation can be modulated to induce local versus systemic immune activation. At lower doses, intratumoral dosing of STING agonists can produce a robust tumor-specific T-cell response capable of ablating a target tumor at a site distal to the STING agonist administration. At higher doses, the distal anti-tumor response is reduced, and ablation of tumor-draining lymph nodes is observed. It is possible to inhibit this ablation of the tumor-draining lymph nodes by co-administration of a TNF antagonist. This co-administration of STING agonists and TNF antagonists can permit the administration of either increased concentrations of STING agonist or STING agonists having greater activity, while maintaining effective tumor control and generation of an anti-tumor adaptive immune response.
9.WO/2021/087114ANTI-ANGIOPOIETIN-LIKE 4 (ANGPTL4) ANTIBODIES AND METHODS OF USE
WO 06.05.2021
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/US2020/057964 Applicant UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED Inventor ZHANG, Weizhou
Described herein are anti-angiopoictin-like 4 (ANGPTL4) antibodies and methods of treating disorders associated with elevated expression of ANGPTL4. In one aspect, described herein is an antibody or antigen binding fragment thereof that binds angiopoietin-like 4 (ANGPTL4) comprising amino acid sequences set forth in (a) SEQ ID NOs: 3-8 (Ab-A CDRs), (b) SEQ ID NOs: 13-18 (Ab-B CDRs), (c) SEQ ID NOs: 23-28 (Ab-C CDRs), (d) SEQ ID NOs: 33-38 (Ab-D CDRs), or (e) SEQ ID NOs: 43-48 (Ab-E CDRs).
10.WO/2021/087234LINEAGE REPROGRAMMING AS A CANCER IMMUNOTHERAPY
WO 06.05.2021
Int.Class A61K 35/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
Appl.No PCT/US2020/058170 Applicant THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY Inventor MAJETI, Ravindra
Cancer cells are treated by direct reprogramming to generate antigen presenting cells, which can present tumor antigens and enhance immune responsiveness to the cancer. The direct reprogramming utilizes genetic modification to force expression of transcription factors that drive cells into the myeloid lineage. Compositions and methods are provided for vaccination with cancer cells.